Hong Kong, 19 March 2026—JACOBIO PHARMACEUTICALS GROUP CO., LTD. (JACOBIO-B, 01167) disclosed a Next Day Return detailing a share repurchase conducted on 19 March 2026.

Key transaction details • Quantity repurchased: 150,000 ordinary shares • Price range: HK$6.72–HK$6.78; volume-weighted average price: HK$6.75 • Cash outlay: HK$1.01 million • Method: On-market purchase under the existing repurchase mandate

Updated share structure • Issued shares (excluding treasury) decreased to 786.20 million, down 0.019 % from 18 March 2026. • Treasury shares increased to 5.56 million. • Total issued shares remain unchanged at 791.76 million.

Repurchase mandate utilisation • Mandate authorised on 10 June 2025: up to 78.87 million shares. • Cumulative buybacks under the mandate: 2.54 million shares, equivalent to 0.32 % of the share base on the mandate’s approval date. • Remaining mandate capacity: 76.33 million shares.

Regulatory timeline • Moratorium on new share issues or treasury-share sales runs through 18 April 2026, in line with Main Board Rule 10.06(3)(a).

The company confirmed that the repurchase complied with Hong Kong Listing Rules and its previously filed explanatory statement.